Takeda exits cell therapy research
Takeda will seek an external partner to leverage its cell therapy platform technologies
Takeda will seek an external partner to leverage its cell therapy platform technologies
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
India currently hosts more than 10,075 biotech startups
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
Subscribe To Our Newsletter & Stay Updated